U.S. ↔ treatment-resistant depression

Relations (1)

cross_type 0.30 — supporting 3 facts

The U.S. is the geographic context for clinical research and medical practice regarding treatment-resistant depression, as evidenced by the availability of ketamine treatments [1], mortality studies within the U.S. population [2], and cost-effectiveness analyses of esketamine nasal spray conducted in the United States [3].

Facts (3)

Sources

The Montreal model: an integrative biomedical-psychedelic ... frontiersin.org Frontiers in Psychiatry 2 facts

referenceBrendle et al. (2022) analyzed the cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the United States, utilizing clinical trial efficacy and real-world effectiveness estimates.

referenceLi et al. conducted a cohort study on all-cause mortality in patients with treatment-resistant depression within the US population, published in Annals of General Psychiatry in 2019.

Effects of psychedelics on neurogenesis and broader neuroplasticity link.springer.com Springer 1 fact

claimKetamine is a prescriptible treatment for treatment-resistant depression (TRD) in the USA and Israel, with many other countries implementing this treatment, according to Mathai et al. (2020).